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INTRODUCTION
Colorectal cancers are primarily diseases of the sixth, sev-
enth, and eighth decades of life. The probability of develop-
ing colorectal cancer increases from 0.06% in the first four
decades of life to 3-4% in the sixth and seventh decades in
the United States (1, 2). Incidence of colorectal cancer is ris-
ing and now it ranks fourth common cancer in Korea (3),
and this trend is likely to continue as the proportion of elderly
in the general population increases. 
Chemotherapy has an important role in the management
of colorectal cancer. 5-Fluorouracil (5-FU) based adjuvant
chemotherapy has resulted in increased disease-free and over-
all survivals in stage III colon cancer (4), and palliative chemo-
therapy has extended the lives of patients with metastatic
colorectal cancer and improved the quality of life compared
with best supportive care (5). Moreover, a number of new
agents have become available for the treatment of metastatic
colorectal cancer, e.g., oxaliplatin, irinotecan, and capecitabine.
The FOLFOX-4 regimen has been found to produce response
rates of 30-50%, a progression free survival of 7-9 months,
and overall survivals of 16-20 months in a number of phase
2 and 3 trials, and is generally accepted as the standard first
line chemotherapy in colorectal cancer (6, 7). Though majority
of colorectal cancer patients are elderly, little data is available
on the efficacy and safety of the FOLFOX-4 regimen in elderly
patients. Moreover, patients above 70 yr of age are underrep-
resented in clinical trials and are often denied palliative chemo-
therapy due to a lack of evidence of efficacy and a fear of tox-
icities (8, 9). In the present study, to minimize toxicity and
increase chemotherapy compliance in elderly patients, a reduced
dose intensity (mini-) FOLFOX-4 regimen was used. This
study was undertaken to evaluate toxicity and efficacy of this
mini-FOLFOX-4 regimen in elderly colorectal cancer patients
as a first-line palliative chemotherapy. 
MATERIALS AND METHODS
Using prospective databases, we identified patients older
than 70 yr of age with histologically confirmed adenocarci-
noma of the colon or rectum and who were treated with the
mini-FOLFOX-4 regimen for metastatic or recurrent disease
in Seoul National University Bundang Hospital or Seoul
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Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy
in Elderly Patients with Advanced Colorectal Cancer
To evaluate the toxicity and efficacy of a reduced dose intensity (mini-) FOLFOX-4
regimen as a first-line palliative chemotherapy in elderly patients (≥70 yr of age)
with advanced colorectal cancer, data from prospective databases at Seoul National
University Bundang Hospital and Seoul Municipal Boramae Hospital were analyzed.
A total of 20 patients were enrolled between January 2001 and August 2004, and
were treated with oxaliplatin 65 mg/m
2 on day 1, and with 2-hr infusions of leucovorin
150 mg/m
2 followed by a 5-FU bolus (300 mg/m
2) and 22-hr continuous infusions
(450 mg/m
2) for 2 consecutive days every 2 weeks until progression, unacceptable
toxicity or patient refusal. Sixteen patients were evaluable for response with an over-
all response rate of 43.8%. Median progression-free survival was 4.8 months (95%
CI: 3.0-6.7) and overall survival was 13.5 months (95% CI: 11.1-16.0). The main side
effects were anemia and neutropenia, which were observed in 20.8% and 17.7%,
respectively, of the total cycles administered. There were no grade 4 toxicities and
only one patient suffered from febrile neutropenia. No grade 3 toxicities occurred
except for anemia (5.2%) and vomiting (1.0%). In conclusion, the mini-FOLFOX-4
regimen was found to be well tolerated with acceptable toxicity, and to provide a
benefit for elderly patients with colorectal cancer. 
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Municipal Boramae Hospital. Patients with bidimensionally
measurable lesions were included in the study, but patients
who received another primary chemotherapy were excluded.
Adjuvant chemotherapy was allowed if it had been admin-
istered more than 6 months prior to the diagnosis of metastatic
or recurrent colorectal cancer. Doses of oxaliplatin and 5-FU
in the original FOLFOX-4 regimen were reduced by 25%.
Oxaliplatin 65 mg/m2 was administered intravenously over
2 hr on day 1, and this was followed by a bolus injection of
5-FU 300 mg/m2, followed by a two-hour infusions of leu-
covorin 150 mg/m2, followed by continuous infusion of 5-
FU 450 mg/m2 over 22 hr. Leucovorin, 5-FU bolus, and con-
tinuous infusion were repeated on day 2 of each 14-day cycle.
Treatment was repeated every two weeks until disease pro-
gression, unacceptable toxicity or patient refusal. Treatment
delays and dose modifications were based on complete blood
cell counts taken on the day of the next planned treatment.
Toxicity was graded using the National Cancer Institute
common toxicity criteria (10). Tumor response was assessed
according to standard WHO criteria by CT every 3 to 4 cycles
(11). All patients were treated after obtaining informed con-
sent. Data on treatment, toxicity, response, and disease sta-
tus were prospectively recorded on specially designed forms. 
Statistical analysis
Overall survival was calculated from the 1st day of chemo-
therapy to the date of death. Progression free survival was
calculated from the 1st day of chemotherapy to the date of
disease progression. All survival distributions were calculat-
ed using the Kaplan-Meier method. 
RESULTS
Patient characteristics
Between January 2001 and August 2004, 20 patients ≥
70 yr old were enrolled and administered the mini-FOLFOX-
4 regimen at Seoul National University Bundang Hospital
and at Seoul Municipal Boramae Hospital. All patients had
histologically proven adenocarcinoma of the colon or rectum.
Patient characteristics are shown in Table 1. Median patient
age was 75 yr (range 70-83), and the majority of the study
population were male (16 of 20). Eight patients received adju-
vant chemotherapy: 5-FU plus leucovorin in six patients, and
oral 5-FU in two.
Efficacy
Among twenty patients, 16 patients were evaluable for
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Fig. 1. Kaplan-Meier estimates of overall survival.
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Fig. 2. Kaplan-Meier estimates of progression free survival.
Characteristic No. of patients (n=20)
Sex
Male 16
Female 4
Age (yr)
Median 75
Range 70-83
ECOG performance status
11 0
21 0
Types of cancer
Colon 12
Rectal 8
Prior cancer therapy 
Curative resection 12
Adjuvant chemotherapy 8
Radiation therapy 3
Site of metastasis
Liver 8
Lymph nodes 7
Peritoneal carcinomatosis 4
Lung 6
Bone 2
Table 1. Patient characteristics808 J.H. Kim, D.-Y. Oh, Y.J. Kim, et al.
response. Response evaluations were not possible in four pati-
ents; two patients were lost to follow-up after the 1st cycle
of treatment and two patients refused further treatment after
two cycles, before a response evaluation was conducted. Among
the 16 patients evaluable for response, one achieved complete
response and 6 partial response, giving an overall response
rate per protocol was 43.8% (95% CI: 23.1-66.8) and an over-
all response rate based on intention-to-treatment analysis was
35% (95% CI: 18.1-56.7). An additional 8 patients achieved
stable disease and one progressed. After 19.8 months of median
follow-up duration, overall survival was 13.5 months (95%
CI: 11.1-16.0) and median progression-free survival was 4.8
months (95% CI: 3.0-6.7). Progression free survival curves
and overall survival curves for all patients are shown in Fig. 1,
2. Second line chemotherapy was administered in 13 (65%)
patients.
Toxicity
The incidences of main toxicities per cycle and patient are
summarized in Table 2. A total of 99 cycles were delivered,
and patients received a median of six cycles. The most fre-
quently observed toxicity was anemia, which was reported
in 20.8% of the 99 cycles. Neutropenia was mild and occurred
in 17.7% of the 99 cycles, and there was only one episode of
febrile neutropenia. No grade 3 or 4 toxicities occurred, except
for grade 3 anemia and vomiting which were observed in 5
and 1 cycles, respectively. There was no treatment related
mortality. 
Dose intensity
Relative dose intensities of oxaliplatin, bolus 5-FU, and
continuous infusion 5-FU were 94.4%, 91.9%, and 89.6%.
These converted to 70.8%, 68.9%, and 67.2% of their full
doses in the original FOLFOX-4 regimen. The median cumu-
lative dose of oxaliplatin was 353.5 mg/m2.
DISCUSSION
In this study we assessed the clinical efficacy and safety of
a mini-FOLFOX-4 regimen in elderly patients with metastatic
or recurrent colorectal cancer. This regimen showed a response
rate of 43.8% per protocol, a progression free survival of 4.8
months, and a median survival of 13.5 months, and was well
tolerated with a <5% incidence of grade 3 or 4 toxicities.
For decades 5-FU was the mainstay palliative chemother-
apy for colorectal cancer, until agents such as oxaliplatin and
irinotecan were introduced in the 1990’s. Combination pro-
tocols of oxaliplatin with 5-FU plus leucovorin, known as
FOLFOX regimens, have shown remarkable synergy and
efficacy in preclinical models and in clinical trials (12). The
FOLFOX-4 regimen became the standard therapy for advanced
colorectal cancer patients after randomized phase III trials
revealed significantly superior, response rates, time to progres-
sion, and overall survival of 45%, and 8.7 and 19.5 months,
respectively, versus the IFL regimen (31%, 6.9 months, 15.0
months, respectively), which incorporated bolus 5-FU, leu-
covorin, and another new agent, irinotecan (7). Here, we chose
FOLFOX-4 as a first-line palliative chemotherapy in these
elderly patients because of its superior efficacy and favorable
toxicity profile versus irinotecan, which shows more severe and
frequent toxicities such as nausea, vomiting, diarrhea and febrile
neutropenia (7). Chemotherapy doses were reduced to decrease
toxicities of diarrhea, mucositis and febrile neutropenia, which
may be severe and life-threatening in elderly patients. 
Although elderly patients comprise a significant propor-
tion of those with colorectal cancer, they are underrepresent-
ed in most clinical trials (8, 9). Several studies performed in
Europe and in the United States have reported similar bene-
fits from 5-FU based chemotherapies in the elderly, at main-
tained dose intensities (13-16). Popescu et al. compared the
outcome of palliative chemotherapy in 658 patients with
colorectal cancer younger than 70 yr old and in 186 patients
older than 70 yr and found no difference between the two
groups in terms of dose-intensity, response rate, or median
failure-free survival time (16). However, median overall sur-
Type of toxicity (n=99)
Toxicity grades
12 3 4
Type of toxicity (n=18)
Toxicity grades
12 3 4
(A)
Hematologic toxicity
Anemia 13 (13.5%) 2 (2.1%) 5 (5.2%) 0
Neutropenia 12 (12.5%) 5 (5.2%) 0 0
Thrombocytopenia 4 (4.2%) 1 (1.0%) 0 0
Non-hematologic toxicity
Nausea/vomiting 3 (3.1%) 0 1 (1.0%) 0
Diarrhea 2 (2.1%) 0 0 0
Peripheral neuropathy 2 (2.1%) 1 (1.0%) 0 0
Fatigue 12 (12.5%) 9 (9.1%) 1 (1.0%) 0
Stomatitis 2 (2.1%) 6 (6.1%) 0 0
Alopecia 2 (2.1%) 4 (4.2%) 0 0
(B)
Hematologic toxicity
Anemia 4 (22.2%) 1 (5.6%) 2 (11.1%) 0
Neutropenia 5 (27.8%) 2 (11.1%) 0 0
Thrombocytopenia 1 (5.6%) 1 (5.6%) 0 0
Non-hematologic toxicity
Nausea/vomiting 3 (16.7%) 0 1 (5.6%) 0
Diarrhea 1 (5.6%) 0 0 0
Peripheral neuropathy 1 (5.6%) 1 (5.6%) 0 0
Fatigue 5 (27.8%) 4 (22.2%) 1 (5.6%) 0
Stomatitis 1 (5.6%) 2 (11.1%) 0 0
Alopecia 1 (5.6%) 2 (11.1%) 0 0
Table 2. Incidence of hematologic and non-hematologic toxici-
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vival was significantly shorter in the older patients (9.6 vs.
11.5 months), though the authors suggested that multiple
comorbidities and non-cancer related deaths are likely causes
of this shorter overall survival. Data on new agents are even
more scarce, and few clinical trials have assessed efficacy and
tolerability of palliative FOLFOX regimens in elderly patients
with advanced colorectal cancer. Mattioli et al. reported a
response rate of 32.6% and Berretta et al. reported similar
tolerabilities and response rates for the FOLFOX-2 regimen
in patients younger and older than 65 yr (17, 18). The 43.8%
response rate achieved in the present study is comparable to
those of previous FOLFOX studies, and the overall survival of
13.5 months is comparable to those of most published series
in the elderly (15, 16). However, progression free survival
was shorter in the present study than in those mentioned
above. This may be due to the reduced dose intensities used
and the small numbers of cycles given. The median time to
response for the FOLFOX-4 regimen was found to be nine
weeks in most clinical trials (6). In the present study, a median
of six cycles of chemotherapy were given and 9 of the 20
received fewer than five cycles. Of these nine patients, the
reasons for stopping chemotherapy were; progressive disease
in one, toxicity in one, and patient refusal in seven. 
The Mini-FOLFOX-4 regimen showed little toxicity and
was found to be remarkably safe in our elderly patients includ-
ing ten patients with an ECOG performance status of 2. The
incidence of oxaliplatin-induced neurotoxicity was lower
than those in published series probably due to the low cumu-
lative dose of oxaliplatin given. In most clinical trials, the
incidence of sensory symptoms causing functional impairment
(grade 3 toxicity) was found to rise after a cumulative dose
of 700-800 mg/m2 (6, 19), whereas the median cumulative
dose of oxaliplatin administered was only 353.5 mg/m2 in
the present study. Moreover, the incidence of neutropenia
(17.7%) was much lower in our study than that of grade 3/4
neutropenia in a phase 3 trial (41.7% of patients) by de Gra-
mont et al. (6), which is probably due to the reduced 5-FU
bolus dose administered. 
Elderly patients are often denied palliative chemotherapy.
Surveillance, epidemiologic, and End Results data showed
that chemotherapy in advanced colorectal cancer patients falls
with increasing age, e.g., the percentages of stage IV colorec-
tal cancer patients treated were 45%, 41%, 27%, 18%, and
5% in those aged 65-69, 70-74, 75-79, 80-84, and 85+ in
the United States (20). Currently, there are few data available
on the usage of chemotherapy for the treatment of elderly
patients in Korea (21-23). In our study, a significant propor-
tion of patients refused further treatment in the absence of
progressive disease or due to unacceptable toxicities, and five
patients stopped chemotherapy after six cycles for non-med-
ical reasons, many of which were cost-related. 
In conclusion, the mini-FOLFOX-4 regimen was found
to be well tolerated with little toxicity, and provided similar
benefit for the elderly colorectal cancer patients. Reduced
intensity FOLFOX-4 may be a valuable option for elderly
patients with poor performance or for those that refuse chemo-
therapy for fear of toxic reactions. Patients with a good per-
formance status could be offered palliative chemotherapy at
full dose, and be included in research studies, to provide evi-
dence that chemotherapy is beneficial in elderly patients.
Moreover, patient-tailored treatments based on comprehen-
sive geriatric and comorbidity scale assessments, rather than
fixed dose reductions based on chronological age alone, may
provide more benefit to elderly patients with cancer. 
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